RealClearDefense Op-Ed: China's Pharmaceutical Supply Chain Dominance Threatens US National Security
If the sole-source chemical dependency the article describes is accurate, a sustained disruption to Chinese API exports — whether from sanctions, conflict, or export controls Beijing imposes — would hit generic drug manufacturers hardest, since their margins leave no room to absorb spot-market premiums for alternative sourcing.
The BIOSECURE Act debate in Congress has already surfaced this vulnerability; if that legislation advances in the next session, the companies most exposed are contract manufacturers with no domestic API supply agreements already in place.
The argument is not new, but the article adds a concrete structural claim: hundreds of US-approved drugs rely on at least one chemical produced solely in China, a concentration Beijing reinforced through heavy subsidies to domestic chemical and drug-ingredient producers.
That pricing advantage has displaced competing suppliers elsewhere, leaving US pharmaceutical manufacturers without a credible near-term alternative source.
Congress and the FDA have addressed semiconductor and rare earth dependencies with dedicated legislation and funding; the article argues biotech and pharmaceutical inputs have not received equivalent policy attention despite a faster-moving competitive environment.
Which specific drug categories or therapeutic classes have the highest concentration of China-only starting materials — and has DoD or HHS mapped that exposure against wartime consumption requirements?
Fault Lines
Strategic intelligence, synthesized daily — with a public track record. Every call graded against what actually happened.